Entity Details

Primary name GFPT1_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ06210
EntryNameGFPT1_HUMAN
FullNameGlutamine--fructose-6-phosphate aminotransferase [isomerizing] 1
TaxID9606
Evidenceevidence at protein level
Length699
SequenceStatuscomplete
DateCreated1994-06-01
DateModified2021-06-02

Ontological Relatives

GenesGFPT1

GO terms

Show/Hide Table
GOName
GO:0004360 glutamine-fructose-6-phosphate transaminase (isomerizing) activity
GO:0005829 cytosol
GO:0006002 fructose 6-phosphate metabolic process
GO:0006047 UDP-N-acetylglucosamine metabolic process
GO:0006048 UDP-N-acetylglucosamine biosynthetic process
GO:0006112 energy reserve metabolic process
GO:0006487 protein N-linked glycosylation
GO:0006541 glutamine metabolic process
GO:0032922 circadian regulation of gene expression
GO:0036498 IRE1-mediated unfolded protein response
GO:0070062 extracellular exosome
GO:0097367 carbohydrate derivative binding

Subcellular Location

Show/Hide Table

Domains

Show/Hide Table
DomainNameCategoryType
IPR001347 SIS domainDomainDomain
IPR005855 Glucosamine-fructose-6-phosphate aminotransferase, isomerisingFamilyFamily
IPR017932 Glutamine amidotransferase type 2 domainDomainDomain
IPR029055 Nucleophile aminohydrolases, N-terminalFamilyHomologous superfamily
IPR035466 GlmS/AgaS, SIS domain 1DomainDomain
IPR035490 GlmS/FrlB, SIS domain 2DomainDomain

Diseases

Show/Hide Table
Disease IDSourceNameDescription
610542 OMIMMyasthenic syndrome, congenital, 12 (CMS12)A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS12 is characterized by onset of proximal muscle weakness in the first decade. Individuals with this condition have a recognizable pattern of weakness of shoulder and pelvic girdle muscles, and sparing of ocular or facial muscles. EMG classically shows a decremental response to repeated nerve stimulation, a sign of neuromuscular junction dysfunction. Affected individuals show a favorable response to acetylcholinesterase (AChE) inhibitors. The disease is caused by variants affecting the gene represented in this entry.